Jin Yang Pharmaceutical（A007370）株式概要ジンヤン製薬株式会社は韓国で医薬品事業に従事している。 詳細A007370 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績1/6財務の健全性1/6配当金1/6報酬株価収益率（ 2.3 x） KR市場（ 11.8 x）を下回っています。リスク分析利払いは収益で十分にカバーされない 財務結果に影響を与える大きな一時的項目 意味のある時価総額がありません ( ₩52B )すべてのリスクチェックを見るA007370 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,122 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA487,122 investors already sharing narrativesYour Fair Value₩Current Price₩4.00k56.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7b269b2016201920222025202620282031Revenue ₩269.2bEarnings ₩49.1bAdvancedSet Fair ValueView all narrativesJin Yang Pharmaceutical Co., Ltd. 競合他社Kukje PharmaSymbol: KOSE:A002720Market cap: ₩68.9bMYUNGMOON PharmLtdSymbol: KOSE:A017180Market cap: ₩42.0bYuyu PharmaSymbol: KOSE:A000220Market cap: ₩60.0bSinsin PharmaceuticalSymbol: KOSDAQ:A002800Market cap: ₩68.0b価格と性能株価の高値、安値、推移の概要Jin Yang Pharmaceutical過去の株価現在の株価₩4,000.0052週高値₩6,110.0052週安値₩3,350.00ベータ0.331ヶ月の変化5.40%3ヶ月変化-14.80%1年変化-33.99%3年間の変化-32.20%5年間の変化-41.86%IPOからの変化101.61%最新ニュース分析記事 • May 27Beyond Lackluster Earnings: Potential Concerns For Jin Yang Pharmaceutical's (KOSDAQ:007370) ShareholdersJin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock wasn't much affected by its recent lackluster earnings...Buy Or Sell Opportunity • May 14Now 22% overvaluedOver the last 90 days, the stock has fallen 6.1% to ₩4,695. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 4.6% to ₩4,625. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.New Risk • Mar 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 3,533% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩59.6b market cap, or US$39.4m).Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,640. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.Buy Or Sell Opportunity • Mar 05Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,630. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.最新情報をもっと見るRecent updates分析記事 • May 27Beyond Lackluster Earnings: Potential Concerns For Jin Yang Pharmaceutical's (KOSDAQ:007370) ShareholdersJin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock wasn't much affected by its recent lackluster earnings...Buy Or Sell Opportunity • May 14Now 22% overvaluedOver the last 90 days, the stock has fallen 6.1% to ₩4,695. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 4.6% to ₩4,625. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.New Risk • Mar 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 3,533% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩59.6b market cap, or US$39.4m).Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,640. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.Buy Or Sell Opportunity • Mar 05Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,630. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩4,370, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 26% over the past three years.お知らせ • Feb 24Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 2.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).New Risk • Nov 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (₩61.9b market cap, or US$42.1m).Declared Dividend • Nov 08Dividend of ₩150 announcedDividend of ₩150 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 2.9%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 11% per year over the past 4 years and payments have been stable during that time.お知らせ • Nov 07Jin Yang Pharmaceutical Co., Ltd. announces Annual dividend, payable on April 20, 2026Jin Yang Pharmaceutical Co., Ltd. announced Annual dividend of KRW 150.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.分析記事 • May 24We Think Shareholders Should Be Aware Of Some Factors Beyond Jin Yang Pharmaceutical's (KOSDAQ:007370) ProfitDespite posting strong earnings, Jin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock didn't move much over the...お知らせ • Feb 25Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South Korea分析記事 • Jan 06Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Soars 39% But It's A Story Of Risk Vs RewardDespite an already strong run, Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shares have been powering on, with a...New Risk • Jan 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (70% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Market cap is less than US$100m (₩89.7b market cap, or US$61.5m).Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 35%After last week's 35% share price gain to ₩7,850, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.Declared Dividend • Dec 19Dividend of ₩150 announcedShareholders will receive a dividend of ₩150. Ex-date: 27th December 2024 Payment date: 1st January 1970 Dividend yield will be 2.5%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 14% per year over the past 3 years and payments have been stable during that time.Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩6,180, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 12x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 3.0% over the past three years.分析記事 • Nov 22Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong EarningsEven though Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) posted strong earnings recently, the stock hasn't...Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: ₩2,008 (vs ₩363 in 3Q 2023)Third quarter 2024 results: EPS: ₩2,008 (up from ₩363 in 3Q 2023). Revenue: ₩31.6b (up 31% from 3Q 2023). Net income: ₩22.2b (up 468% from 3Q 2023). Profit margin: 70% (up from 16% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.New Risk • Aug 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.5% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.5% net profit margin). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩64.1b market cap, or US$48.0m).分析記事 • Aug 19Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For GrowthDespite an already strong run, Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shares have been powering on, with a...Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩7,250, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 1.8% over the past three years.New Risk • Aug 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩62.0b market cap, or US$45.9m).分析記事 • Aug 12These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably WellHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • May 23Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak ProfitThe subdued market reaction suggests that Jin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) recent earnings didn't...New Risk • Mar 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Market cap is less than US$100m (₩63.8b market cap, or US$48.0m).Upcoming Dividend • Dec 20Upcoming dividend of ₩150 per share at 2.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩363 (vs ₩560 in 3Q 2022)Third quarter 2023 results: EPS: ₩363 (down from ₩560 in 3Q 2022). Revenue: ₩24.1b (up 10% from 3Q 2022). Net income: ₩3.92b (down 37% from 3Q 2022). Profit margin: 16% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • May 14First quarter 2023 earnings released: EPS: ₩256 (vs ₩153 in 1Q 2022)First quarter 2023 results: EPS: ₩256 (up from ₩153 in 1Q 2022). Revenue: ₩22.4b (up 27% from 1Q 2022). Net income: ₩2.76b (up 61% from 1Q 2022). Profit margin: 12% (up from 9.7% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 20 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: ₩560 (vs ₩186 in 3Q 2021)Third quarter 2022 results: EPS: ₩560 (up from ₩186 in 3Q 2021). Revenue: ₩21.8b (up 40% from 3Q 2021). Net income: ₩6.18b (up 198% from 3Q 2021). Profit margin: 28% (up from 13% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Inaugural dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Jin Yang Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₩6,420, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 86% over the past three years.Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩7,580, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₩8,300, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 121% over the past three years.分析記事 • Mar 22A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)In this article we are going to estimate the intrinsic value of Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) by...分析記事 • Mar 04Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting StockLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Is New 90 Day High Low • Feb 23New 90-day low: ₩5,940The company is down 20% from its price of ₩7,410 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.お知らせ • Feb 17Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021, at 09:00 Korea Standard Time.分析記事 • Feb 11These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt SafelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is New 90 Day High Low • Jan 28New 90-day low: ₩6,300The company is down 2.0% from its price of ₩6,440 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.分析記事 • Jan 21Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?It is hard to get excited after looking at Jin Yang Pharmaceutical's (KOSDAQ:007370) recent performance, when its stock...分析記事 • Jan 04Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?It hasn't been the best quarter for Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shareholders, since the share...Upcoming Dividend • Dec 22Upcoming Dividend of ₩100.00 Per ShareWill be paid on the 13th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in April 2010. The average dividend yield among industry peers is 0.6%.分析記事 • Dec 17We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory EarningsStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...分析記事 • Nov 30Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth WatchingSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...Is New 90 Day High Low • Oct 26New 90-day low: ₩6,350The company is down 8.0% from its price of ₩6,900 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.株主還元A007370KR PharmaceuticalsKR 市場7D2.3%9.9%0.5%1Y-34.0%-1.8%89.4%株主還元を見る業界別リターン: A007370過去 1 年間で-1.8 % の収益を上げたKR Pharmaceuticals業界を下回りました。リターン対市場: A007370は、過去 1 年間で89.4 % のリターンを上げたKR市場を下回りました。価格変動Is A007370's price volatile compared to industry and market?A007370 volatilityA007370 Average Weekly Movement6.0%Pharmaceuticals Industry Average Movement7.3%Market Average Movement9.9%10% most volatile stocks in KR Market17.7%10% least volatile stocks in KR Market5.1%安定した株価: A007370 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A007370の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1971n/aJae-Joon Choiwww.jinyangpharm.comジンヤン・ファーマシューティカル社は韓国で医薬品事業に従事している。同社は、抗糖尿病薬、抗ウイルス薬、抗高血圧薬、抗凝血薬、抗ヒスタミン薬、解熱鎮痛薬、消化器系、呼吸器系、精神神経系の製品を提供している。また、泌尿生殖器系、抗骨粗鬆症薬、抗菌薬、抗生物質、一般用医薬品の解熱鎮痛薬も提供している。また、消化器系、泌尿生殖器系、精神神経系、循環器系、皮膚科系の製品も提供している。さらに、筋弛緩薬、抗高脂血症薬、マルチビタミン・栄養剤、肝臓薬、抗悪性腫瘍薬、抗肥満薬、歯科治療薬、眼科治療薬などの製品も提供している。ジンヤン製薬は1971年に設立され、韓国ソウルに本社を置く。もっと見るJin Yang Pharmaceutical Co., Ltd. 基礎のまとめJin Yang Pharmaceutical の収益と売上を時価総額と比較するとどうか。A007370 基礎統計学時価総額₩51.64b収益（TTM）₩22.29b売上高(TTM)₩122.15b2.3xPER（株価収益率0.4xP/SレシオA007370 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A007370 損益計算書（TTM）収益₩122.15b売上原価₩42.04b売上総利益₩80.11bその他の費用₩57.82b収益₩22.29b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）1.73kグロス・マージン65.58%純利益率18.25%有利子負債／自己資本比率47.4%A007370 の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.8%現在の配当利回りn/a配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/12 23:53終値2026/08/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Jin Yang Pharmaceutical Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • May 27Beyond Lackluster Earnings: Potential Concerns For Jin Yang Pharmaceutical's (KOSDAQ:007370) ShareholdersJin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock wasn't much affected by its recent lackluster earnings...
Buy Or Sell Opportunity • May 14Now 22% overvaluedOver the last 90 days, the stock has fallen 6.1% to ₩4,695. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.
Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 4.6% to ₩4,625. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.
New Risk • Mar 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 3,533% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩59.6b market cap, or US$39.4m).
Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,640. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.
Buy Or Sell Opportunity • Mar 05Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,630. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.
分析記事 • May 27Beyond Lackluster Earnings: Potential Concerns For Jin Yang Pharmaceutical's (KOSDAQ:007370) ShareholdersJin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock wasn't much affected by its recent lackluster earnings...
Buy Or Sell Opportunity • May 14Now 22% overvaluedOver the last 90 days, the stock has fallen 6.1% to ₩4,695. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.
Buy Or Sell Opportunity • Apr 13Now 20% overvaluedOver the last 90 days, the stock has fallen 4.6% to ₩4,625. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%.
New Risk • Mar 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 3,533% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩59.6b market cap, or US$39.4m).
Buy Or Sell Opportunity • Mar 20Now 21% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,640. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.
Buy Or Sell Opportunity • Mar 05Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to ₩4,630. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩4,370, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 26% over the past three years.
お知らせ • Feb 24Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 2.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).
New Risk • Nov 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (₩61.9b market cap, or US$42.1m).
Declared Dividend • Nov 08Dividend of ₩150 announcedDividend of ₩150 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 2.9%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 11% per year over the past 4 years and payments have been stable during that time.
お知らせ • Nov 07Jin Yang Pharmaceutical Co., Ltd. announces Annual dividend, payable on April 20, 2026Jin Yang Pharmaceutical Co., Ltd. announced Annual dividend of KRW 150.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
分析記事 • May 24We Think Shareholders Should Be Aware Of Some Factors Beyond Jin Yang Pharmaceutical's (KOSDAQ:007370) ProfitDespite posting strong earnings, Jin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) stock didn't move much over the...
お知らせ • Feb 25Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South Korea
分析記事 • Jan 06Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Soars 39% But It's A Story Of Risk Vs RewardDespite an already strong run, Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shares have been powering on, with a...
New Risk • Jan 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (70% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Market cap is less than US$100m (₩89.7b market cap, or US$61.5m).
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 35%After last week's 35% share price gain to ₩7,850, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.
Declared Dividend • Dec 19Dividend of ₩150 announcedShareholders will receive a dividend of ₩150. Ex-date: 27th December 2024 Payment date: 1st January 1970 Dividend yield will be 2.5%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 14% per year over the past 3 years and payments have been stable during that time.
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩6,180, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 12x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 3.0% over the past three years.
分析記事 • Nov 22Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong EarningsEven though Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) posted strong earnings recently, the stock hasn't...
Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: ₩2,008 (vs ₩363 in 3Q 2023)Third quarter 2024 results: EPS: ₩2,008 (up from ₩363 in 3Q 2023). Revenue: ₩31.6b (up 31% from 3Q 2023). Net income: ₩22.2b (up 468% from 3Q 2023). Profit margin: 70% (up from 16% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
New Risk • Aug 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.5% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.5% net profit margin). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩64.1b market cap, or US$48.0m).
分析記事 • Aug 19Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For GrowthDespite an already strong run, Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shares have been powering on, with a...
Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩7,250, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 1.8% over the past three years.
New Risk • Aug 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩62.0b market cap, or US$45.9m).
分析記事 • Aug 12These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably WellHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • May 23Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak ProfitThe subdued market reaction suggests that Jin Yang Pharmaceutical Co., Ltd.'s ( KOSDAQ:007370 ) recent earnings didn't...
New Risk • Mar 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Market cap is less than US$100m (₩63.8b market cap, or US$48.0m).
Upcoming Dividend • Dec 20Upcoming dividend of ₩150 per share at 2.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩363 (vs ₩560 in 3Q 2022)Third quarter 2023 results: EPS: ₩363 (down from ₩560 in 3Q 2022). Revenue: ₩24.1b (up 10% from 3Q 2022). Net income: ₩3.92b (down 37% from 3Q 2022). Profit margin: 16% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • May 14First quarter 2023 earnings released: EPS: ₩256 (vs ₩153 in 1Q 2022)First quarter 2023 results: EPS: ₩256 (up from ₩153 in 1Q 2022). Revenue: ₩22.4b (up 27% from 1Q 2022). Net income: ₩2.76b (up 61% from 1Q 2022). Profit margin: 12% (up from 9.7% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 20 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: ₩560 (vs ₩186 in 3Q 2021)Third quarter 2022 results: EPS: ₩560 (up from ₩186 in 3Q 2021). Revenue: ₩21.8b (up 40% from 3Q 2021). Net income: ₩6.18b (up 198% from 3Q 2021). Profit margin: 28% (up from 13% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Inaugural dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Jin Yang Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₩6,420, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 86% over the past three years.
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩7,580, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₩8,300, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 121% over the past three years.
分析記事 • Mar 22A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)In this article we are going to estimate the intrinsic value of Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) by...
分析記事 • Mar 04Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting StockLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Is New 90 Day High Low • Feb 23New 90-day low: ₩5,940The company is down 20% from its price of ₩7,410 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
お知らせ • Feb 17Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021, at 09:00 Korea Standard Time.
分析記事 • Feb 11These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt SafelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Is New 90 Day High Low • Jan 28New 90-day low: ₩6,300The company is down 2.0% from its price of ₩6,440 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
分析記事 • Jan 21Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?It is hard to get excited after looking at Jin Yang Pharmaceutical's (KOSDAQ:007370) recent performance, when its stock...
分析記事 • Jan 04Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?It hasn't been the best quarter for Jin Yang Pharmaceutical Co., Ltd. ( KOSDAQ:007370 ) shareholders, since the share...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩100.00 Per ShareWill be paid on the 13th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in April 2010. The average dividend yield among industry peers is 0.6%.
分析記事 • Dec 17We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory EarningsStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...
分析記事 • Nov 30Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth WatchingSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
Is New 90 Day High Low • Oct 26New 90-day low: ₩6,350The company is down 8.0% from its price of ₩6,900 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
